


CLAIMS

1. A bicyclo derivative represented by the following general formula (1):




5 [wherein R¹ is hydrogen atom, halogen atom, carboxyl group, C₁ to C₄ alkyl group which may be substituted with hydroxy group, or a substituted or unsubstituted aryl group; X is CH₂, CHF, CF₂, CHOH, S or O; and n is an integer of 1 to 3.], or a pharmaceutically acceptable salt thereof.

10 2. The bicyclo derivative according to claim 1, wherein in the general formula (1), R¹ is a hydrogen atom, X is CH₂, CHF, CF₂, CHOH, S or O, and n is an integer of 1 to 3, or a pharmaceutically acceptable salt thereof.

15 3. The bicyclo derivative according to claim 1, wherein in the general formula (1), R¹ is a halogen atom, X is CH₂, CHF, CF₂, CHOH, S or O, and n is an integer of 1 to 3, or a pharmaceutically acceptable salt thereof.

4. The bicyclo derivative according to claim 1, wherein the compound represented by the general formula (1) is a compound
20 represented by the following general formula (2):



[wherein X is CH₂, CHF, CF₂, CHOH, S or O; and n is an integer of 1 to 3.], or a pharmaceutically acceptable salt thereof.

5. The bicyclo derivative according to claim 1, wherein in
 5 the general formula (1), R¹ is a C₁ to C₄ alkyl group that may be substituted with hydroxy group; X is CH₂, CHF, CF₂, CHOH, S or O; and n is an integer of 1 to 3, or a pharmaceutically acceptable salt thereof.

6. A pharmaceutical product containing as an active
 10 ingredient the bicyclo derivative of claim 1 or a pharmaceutically acceptable salt thereof.

7. A DPP-IV inhibitor containing as an active ingredient the bicyclo derivative of claim 1 or a pharmaceutically acceptable salt thereof.

15 8. A therapeutic agent for a disease involving DPP-IV containing as an active ingredient the bicyclo derivative of claim 1 or a pharmaceutically acceptable salt thereof.

9. The therapeutic agent according to claim 8, wherein the
 20 disease involving DPP-IV is diabetes or associated diabetic complication.